Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

Ähnliche Einträge

• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  von: Tomczyk, Sara, et al.
  Veröffentlicht: (2014)
• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  von: Bennett, Nancy M., et al.
  Veröffentlicht: (2013)
• Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years
  von: Black, Carla L., et al.
  Veröffentlicht: (2017)
• 596 Potential public health impact of 13-valent pneumococcal conjugate vaccine use among US adults 65 years of age or older
  von: Pilishvili, Tamara, et al.
  Veröffentlicht: (2014)
• Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
  von: Peterson, James T., et al.
  Veröffentlicht: (2018)